Vol. XXXV, n. 3, 2008 ISSN: 0390-6663


CLINICAL AND EXPERIMENTAL
OBSTETRICS & GYNECOLOGY

an International Journal


Editors-in-Chief
A. Onnis
Montréal (CND)
J.H. Check
Camden, NJ (USA)


Associate Editors
M. Marchetti
Montréal (CND)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Audet-Lapointe P., Montréal (Canada)
Axt-Fliedner R., Lübeck (Germany)
Basta A., Krakow (Poland)
Bender H.J., Dusseldorf (Germany)
Bhattacharya N., Calcutta (India)
Bonilla Musoles F., Valencia (Spain)
Charkviani T., Tbilisi (Georgia)
Dargent D., Lyon (France)
Dexeus S., Barcelona (Spain)
Di Paola G., Buenos Aires (Argentina)
Eskes T.K.A.B.,Nijmegen (The Netherlands)
Franchi M., Verona (Italy)
Friedrich M., Homburg (Germany)
Gomel V., Vancouver (Canada)
Gorins A., Paris (France)
Holub Z., Kladno (Czech Republic)
Jordan J.A., Birmingham, England (UK)
Kaplan B., Petach Tikva (Israel)
Kralj B., Ljubljana (Slovenia)
Lalonde A.B., Ottawa (Canada)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Meden-Vrtovec H., Ljubljana (Slovenia)
Ohara N., Kobe (Japan)
Papadopoulos N., Alexandroupolis (Greece)
Rakar S., Ljubljana (Slovenia)
Sciarra J.J., Chicago, IL (USA)
Stelmachow J., Warsaw (Poland)
Varras M.N., Athens (Greece)
Vîrtej P., Bucharest (Romania)
Winter R., Graz (Austria)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - http://www.irog.net/

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY (ISSN 0390-6663) publishes original work, preferably brief reports, in the fields of Gynecology, Obstetrics, Fetal Medicine, Gynecological Endocrinology and related subjects. (Fertility and Sterility, Menopause, Uro-gynecology, Ultrasound in Obstetrics and Gynecology, Sexually Transmitted Diseases).The Journal is covered by INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica.

CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY is issued every three months in one volume per year by IROG CANADA Inc. Montréal. Printed in Italy by "La Garangola", Tipografia Editrice - Via E. Dalla Costa, 6 -35129 Padova (Italy).

 

Clinical and Experimental Obstetrics and Gynecology
http://www.irog.net/


General Information

CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY (ISSN 0390-6663) publishes original peer-reviewed work, preferably brief reports, in the fields of Gynecology, Obstetrics, Fetal Medicine, Gynecological Endocrinology, Fertility and Sterility, Menopause, Uro-gynecology, Ultrasound diagnosis in Obstetrics and Gynecology, Sexually transmitted diseases and related topics. It is indexed in INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica.

AIMS AND SCOPE
Since its inception, the CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY Journal has had the primary aim to assemble and diffuse scientific researches, particularly original researches, contributions, reviews, and proceedings of meetings in every field of the Discipline.
Today its large diffusion all over the world allows us to collect high quality papers and clinical reports on many interesting studies from every country, even from developing countries. This is the target goal of the Journal – aiming at the diffusion of knowledge and advances in female genital diseases.
This publication tries to cover all aspects of obstetrics and gynecology in an interdisciplinary approach among gynecologists, epidemiologists, pathologists, oncologists, radiologists, microbiologists, surgeons, urologists, neonatologists, genetists and so on.
The first target goal of the Journal is to publish high quality papers in the shortest time possible. Research papers, editorial reviews, case reports, technical notes, book reviews and letters to the Editor are published.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION
The Journal is issued every three months (January, April, July and October); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.
Subscriptions include four issues per year plus supplements and monographs and all official communications of Meetings, Courses, Symposia and all scientific activities in the fields of Obstetrics and Gynecology and related topics.
Subscriptions are entered with prepayment only. The annual subscription is $280 US for Institutions and $170 US for Individuals all over the world. For air mail add $20. Single copies prepaid cost $75.00 US.
Send subscription requests with cheque or credit card payment (Amex - Visa - Diners - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3, Canada. Only US Funds are accepted.
Claims for missing issues can be honored up to six months. Changes of address: allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) - better if accompanied by a mailing label from a recent issue and should be sent to the printer La Garangola, Via E. Dalla Costa, 6 - 35129 Padova (Italy) - also by Tel. +39.049.8075557, Fax +39.049.7806580. Claims should be made within six months of publication date. Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.
Single copies and back issue and volume information is available from the printer La Garangola, Padua, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.
All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), Tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.




Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.


© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 -Fax (514) 4854513 - Printed in Italy by "La Garangola" - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua's Court n. 633 - 28-6-1979
 
Clinical and Experimental Obstetrics & Gynecology - Vol. XXXV, n. 3, 2008
CONTENTS  
EDITORIAL ARTICLES  
Action of progesterone receptor modulators on uterine leiomyomas 165
N. Ohara - Kobe, JAPAN
Update on action of progesterone receptor modulators in uterine leiomyomas.
 
 
ORIGINAL ARTICLES  
Reproductive Biology Section  
Improved pregnancy outcome for women with decreased ovarian oocyte reserve and advanced reproductive age by performing in vitro fertilization-embryo transfer 167
J.H. Check, J. Pinto, J.R. Liss, J.K. Choe - Camden, NJ (USA)
Live deliveries are possible in women of more advanced reproductive age with diminished egg reserve with in vitro fertilization producing the greatest efficacy.
 
Normal pregnancy resulting from a non-pronuclear oocyte at the time of examination for fertilization 170
R.O. Burney, J. Gebhardt,Y. Shu, B. Behr, L.M. Westphal - Stanford, CA (USA)
A normal pregnancy from a non-pronuclear oocyte at the fertilization check suggests that these oocytes represent a source of developmentally competent embryos.
 
General Section  
Inherited thrombophilia screening in Greek women with recurrent fetal loss 172
A. Mougiou, G. Androutsopoulos, M. Karakantza, E. Theodori, G. Decavalas, N. Zoumbos - Rion, GREECE
Inherited thrombophilia screening in Greek women with recurrent fetal loss was carried out.
 
HPV detection and genotyping as an earlier approach in cervical cancer screening of the female genital tract 175
W.M. Krambeck, R.M. Cadidé, E.M. Dalmarco, C.M.M. de Cordova - Blumenau-SC, BRAZIL
The aim of this study was to evaluate PCR results of HPV detection as an earlier approach in cervical cancer screening compared to Papanicolaou and colposcopy exams.
 
Maternal serum mannose-binding lectin in severe preeclampsia 179
N. Çelik, H. Ozan - Bursa, TURKEY
Serum mannose-binding lectin was investigated in preeclampsia.
 
Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population 183
D.M. Kordi Tamandani, R.C. Sobti, M. Shekari - Chandigrah, INDIA
This is the first study to provide evidence for the association of Fas-670 (A/G) gene polymorphism with the risk of cervical cancer in the North Indian population.
 
Silicone gel mammary prostheses: immune pathologies and breastfeeding 187
G. Zoccali, N. Lomartire, G. Mascaretti, M. Giuliani - L’Aquila, ITALY
The silicone gel mammary prosthesis as a risk factor for pregnancy was studied comparing a group of pregnant patients with a control group.
 
Ultrasound assessment of endometrial thickness: correlation with ovarian stimulation and pregnancy rates in IVF cycles 190

D. Giannaris, A. Zourla, C. Chrelias, C. Loghis, D. Kassanos - Athens, GREECE
This study correlates endometrial thickness with IVF outcome in 112 cycles and compares GnRH agonist to antagonist protocols.

 
Cranial imaging spectrum in hypertensive disease of pregnancy 194

S. Topuz, I. Kaleliogˇlu, A.C. Iyibozkurt, S Akhan, R. Has, M. Tunaci, L. Ibrahimogˇlu - Istanbul, TURKEY
CT or MRI findings of 120 patients diagnosed with severe preeclampsia, eclampsia and/or HELLP syndrome are presented.

 
The effect of buserelin acetate on the uterus of adult rats: morphological aspects 198

C.R. Trindade, A.F. Camargos, F.E.L. Pereira - Espírito Santo, BRAZIL
Buserelin induces a progressive blockade of gonadotrophin secretion in female rats, and treatment cessation leads to accentuated estrogen release.

 
Use of GnRH antagonists in ovarian remnant syndrome experimentally induced in rats 202

A. Risvanli, S. Kumru, N. Akpolat, S. Yildiz - Kars, TURKEY
The use of GnRH antagonists in rats with ovarian remnant syndrome reduced duration of the estrogenic affect.

 
Usefulness of symphysis-fundal height in predicting fetal weight in healthy term pregnant women 205

U. Indraccolo, L. Chiocci, P. Rosenberg, L. Nappi, P. Greco - Foligno, ITALY
Symphysis-fundal height is a useful tool for predicting fetal birthweight in healthy term pregnant women.

 
Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome 208

P. Gkogkos, G. Androutsopoulos, P. Vassilakos, G. Panayiotakis, G. Kourounis, G. Decavalas - Rion, Greece
Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome were investigated.

 
Knowledge and general consideration about Pap test screening among women from Finland and Greece 211

G. Iatrakis, S. Zervoudis, P. Peitsidis, M.M. Nikolaki, D. Biba, E. Sotiropoulou - Athens, Greece
A study sample including 400 women from Finland and Greece concerning the general knowledge about Pap test screening is reported.

 
 
CASE REPORTS  
Pregnancy and delivery following sonohysterographic lysis to treat recurrence after hysteroscopic lysis of severe intrauterine adhesions: a case report 215
F. Taniguchi, H. Suginami - Nara, JAPAN
Sonohysterographic lysis to treat a recurrent intrauterine adhesion led to tubal patency and achievement of pregnancy, and may be an option.
 
A case of body stalk anomaly at 12 weeks of gestation 218
G. Adonakis, N. Spinos, J. Tourikis, H. Hasiotou, K. Loutzi, G. Kourounis - Zante, GREECE
A case of body stalk anomaly diagnosed in the 1st trimester of pregnancy is described.
 
Partial placenta increta and methotrexate therapy: three case reports 221
S. Pinho, S. Sarzedas, S. Pedroso, A. Santos, M. Rebordão, T. Avillez, E. Casal, M. Hermida - Almada, PORTUGAL
Three cases of partial placenta increta treated successfully with methotrexate are reported.
 
Placenta percreta presenting in the first trimester and resulting in severe consumption coagulopathy and hysterectomy: a case report 225
J.C. Papadakis, N. Christodoulou, A. Papageorgiou, M. Rasidaki - Crete, GREECE
A rare case of placenta percreta, encountered during uterine evacuation in the first trimester, resulting in consumptive hysterectomy is presented.
 
A case with diffuse uterine leiomyomatosis and review of the literature 227
A. Coskun, O. Ozdemir, M.A. Vardar, G. Kiran, D. Arikan, C. Ersoz - Kahramanmaras, TURKEY
Diffuse uterine leiomyomatosis is extremely rare. The case of a patient with a huge uterine mass weighing 2,650 g is presented together with a review of the literature.
 
Successful treatment of advanced endometriosis with extremely high CA 125 and moderately elevated CA 15-3 levels 231
M.T. Canda, N. Demir, O. Sezer, L. Doganay - Izmir, TURKEY
A 29-year-old woman, gravida 1, para 1, was admitted to our clinic with persistent pelvic pain and extremely elevated CA 125 and mildly elevated CA 15-3 levels.